The drug etiology of agranulocytosis and aplastic anemia:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York u.a.
Oxford Univ. Press
1991
|
| Schriftenreihe: | Monographs in epidemiology and biostatistics
18 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXIII, 404 S. |
| ISBN: | 0195059832 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV005460984 | ||
| 003 | DE-604 | ||
| 005 | 20141215 | ||
| 007 | t | ||
| 008 | 920807s1991 |||| 00||| engod | ||
| 020 | |a 0195059832 |9 0-19-505983-2 | ||
| 035 | |a (OCoLC)23869236 | ||
| 035 | |a (DE-599)BVBBV005460984 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RA645.A53 | |
| 082 | 0 | |a 616.1/52 |2 20 | |
| 245 | 1 | 0 | |a The drug etiology of agranulocytosis and aplastic anemia |c David W. Kaufman ... With contrib. by Hermann Heimpel ... |
| 264 | 1 | |a New York u.a. |b Oxford Univ. Press |c 1991 | |
| 300 | |a XXIII, 404 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Monographs in epidemiology and biostatistics |v 18 | |
| 610 | 1 | 4 | |a International Agranulocytosis and Aplastic Anemia Study |
| 610 | 2 | 4 | |a International Agranulocytosis and Aplastic Anemia Study |
| 650 | 4 | |a Agranulocytose - Épidémiologie | |
| 650 | 4 | |a Anémie aplastique - Épidémiologie | |
| 650 | 7 | |a Granulopenie |2 gtt | |
| 650 | 7 | |a Pancytopenie |2 gtt | |
| 650 | 4 | |a Pharmacoépidémiologie | |
| 650 | 4 | |a Agranulocytosis |x Epidemiology | |
| 650 | 4 | |a Agranulocytosis |x chemically induced | |
| 650 | 4 | |a Anemia, Aplastic |x chemically induced | |
| 650 | 4 | |a Aplastic anemia |x Epidemiology | |
| 650 | 4 | |a Drugs |x Side effects |x Epidemiology | |
| 650 | 0 | 7 | |a Aplastische Anämie |0 (DE-588)4228474-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Agranulozytose |0 (DE-588)4141632-6 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Agranulozytose |0 (DE-588)4141632-6 |D s |
| 689 | 0 | 1 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Aplastische Anämie |0 (DE-588)4228474-0 |D s |
| 689 | 1 | 1 | |a Arzneimittelnebenwirkung |0 (DE-588)4003134-2 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Kaufman, David |e Sonstige |4 oth | |
| 700 | 1 | |a Heimpel, Hermann |d 1930-2014 |e Sonstige |0 (DE-588)141518006 |4 oth | |
| 830 | 0 | |a Monographs in epidemiology and biostatistics |v 18 |w (DE-604)BV000004952 |9 18 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003417782&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-003417782 | ||
Datensatz im Suchindex
| _version_ | 1804119673664438272 |
|---|---|
| adam_text | MONOGRAPHS IN EPIDEMIOLOGY AND BIOSTATISTICS VOLUME 18 THE DRUG ETIOLOGY
OF AGRANULOCYTOSIS AND APLASTIC ANEMIA DAVID W. KAUFMAN JUDITH P. KELLY
MICHA LEVY SAMUEL SHAPIRO WITH CONTRIBUTIONS BY HERMANN HEIMPEL, THERESA
ANDERSON, AND MEMBERS OF THE INTERNATIONAL AGRANULOCYTOSIS AND APLASTIC
ANEMIA STUDY GROUP NEW YORK OXFORD OXFORD UNIVERSITY PRESS 1991 CONTENTS
1. DRUG-INDUCED AGRANULOCYTOSIS AND APLASTIC ANEMIA: GENERAL
CONSIDERATIONS, 3 1. THE CONCEPT OF DRUG SAFETY, 3 2. AGRANULOCYTOSIS
AND APLASTIC ANEMIA AS DRUG-INDUCED DISEASES, 5 3. EVIDENCE FOR DRUG
INDUCTION OF AGRANULOCYTOSIS, 6 4. EVIDENCE FOR DRUG INDUCTION OF
APLASTIC ANEMIA, 10 5. CONCLUSION, 13 REFERENCES, 13 2. STRATEGIES FOR
OBTAINING INFORMATION ABOUT DRUG EFFECTS, 17 1. BENEFIT, 17 2. RISK, 18
3. THE PRESENT STUDY, 24 REFERENCES, 24 3. THE DISEASES, 27 HERMANN
HEIMPEL 1. AGRANULOCYTOSIS, 29 1.1. DEFINITION, 29 1.2. DIAGNOSIS, 30
1.3. COURSE AND PROGNOSIS, 32 1.4. EVIDENCE FOR INDUCTION OF
AGRANULOCYTOSIS BY ENVIRONMENTAL FACTORS, 33 1.5. DRUGS AND
AGRANULOCYTOSIS: PATHOGENETIC MECHANISMS, 34 2. APLASTIC ANEMIA, 37 2.1.
DEFINITION, 37 2.2. DIAGNOSIS, 38 2.3. COURSE AND PROGNOSIS, 40 2.4.
EVIDENCE FOR INDUCTION OF APLASTIC ANEMIA BY ENVIRONMENTAL FACTORS, 43
2.5. DRUGS AND APLASTIC ANEMIA: PATHOGENETIC MECHANISMS, 44 REFERENCES,
47 XVIII CONTENTS 4. DESIGN OF THE STUDY, 54 1. OBJECTIVES, 54 2.
DEFINITION OF CASES, 54 3. STUDY BASE, 57 4. SAMPLE SIZE ESTIMATES, 59
5. METHODOLOGICAL CONSIDERATIONS IN THE COLLECTION OF DATA, 60 5.1. THE
CLINICAL VERSUS THE EPIDEMIOLOGICAL APPROACH TO THE DETERMINATION OF
CAUSALITY, 60 5.2. SELECTION BIAS, 62 5.3. INFORMATION BIAS, 64 5.4.
MISCLASSIFICATION, 66 REFERENCES, 67 5. METHODS, 70 1. DEFINITION AND
ASCERTAINMENT OF CASES, 70 1.1. OPERATIONAL DEFINITIONS, 70 1.2.
ASCERTAINMENT, 71 1.3. FINAL REVIEW AND ACCEPTANCE, 72 2. SELECTION OF
CONTROLS, 73 3. DATA COLLECTION, 76 3.1. PROCEDURE, 76 3.2.
QUESTIONNAIRE, 77 3.3. QUALITY CONTROL, 82 4. DATA ANALYSIS, 83 4.1.
INCIDENCE RATES, 83 4.2. DEFINITIONS OF EXPOSURE, 85 4.3. ESTIMATES OF
ASSOCIATION, 91 4.4. ESTIMATES OF STATISTICAL STABILITY, 99 4.5.
ESTIMATES OF EXCESS RISK, 101 REFERENCES, 104 : 6. THE STUDY EXPERIENCE,
106 1. ORIGINS OF THE STUDY, 106 2. PILOT STUDY, 107 3. CHANGES IN THE
STUDY POPULATION, 110 3.1. COMMUNITY CONTROLS, 110 3.2. PROBLEMS WITH
HOSPITAL-ACQUIRED CASES OF AGRANULOCYTOSIS, 113 3.3. CHANGES IN THE
DEFINITION OF HOSPITAL CONTROLS FOR COMMUNITY-ACQUIRED AGRANULOCYTOSIS,
117 3.4. AGE RESTRICTION FOR CASES OF AGRANULOCYTOSIS, 118 4.
COMPLETENESS OF CASE ASCERTAINMENT, 119 5. DEFINITION OF ONSET FOR CASES
OF AGRANULOCYTOSIS, 122 CONTENTS XIX 6. INTERIM ANALYSES, 123 6.1.
DEVELOPMENT OF THE EXPOSURE WINDOW FOR AGRANULOCYTOSIS, 124 6.2.
EVALUATION OF MUTUALLY EXCLUSIVE CATEGORIES OF DRUG USE, 127 6.3.
REGIONAL VARIABILITY IN THE RISK OF AGRANULOCYTOSIS AMONG DIPYRONE
USERS, 129 6.4. INTERIM ANALYSES OF APLASTIC ANEMIA, 134 REFERENCES, 134
7. THE STUDY POPULATION, 135 1. AGRANULOCYTOSIS, 135 2. APLASTIC ANEMIA,
140 3. CONTROLS, 142 4. SUMMARY, 147 REFERENCE, 147 8. INCIDENCE OF
AGRANULOCYTOSIS, 148 1. STUDY BASE: OVERALL INCIDENCE, 148 2. INCIDENCE
OF COMMUNITY-ACQUIRED AGRANULOCYTOSIS, ACCORDING TO VARIOUS FACTORS, 148
3. COMMENTS, 151 REFERENCES, 157 9. INCIDENCE OF APLASTIC ANEMIA, 159 1.
STUDY BASE: OVERALL INCIDENCE, 159 2. INCIDENCE ACCORDING TO VARIOUS
FACTORS, 159 3. COMMENTS, 161 REFERENCES, 169 10. NONNARCOTIC ANALGESIC
AND NONSTEROIDAL ANTIINFLAMMATORY DRUGS, 170 1. THE DRUGS, 170 2.
SPECIFIC METHODS, 172 2.1. AGRANULOCYTOSIS, 172 2.2. APLASTIC ANEMIA,
175 3. RESULTS, 176 3.1. AGRANULOCYTOSIS, 176 3.2. APLASTIC ANEMIA, 183
4. SUMMARY OF RESULTS AND CONSIDERATION OF VALIDITY, 186 5. COMMENTS,
191 XX CONTENTS 5.1. DIPYRONE AND OTHER PYRAZOLONES, 191 5.2.
SALICYLATES, 195 5.3. PARACETAMOL AND PHENACETIN, 195 5.4. BUTAZONES,
196 5.5. INDOMETHACIN, 197 5.6. DICLOFENAC AND PIROXICAM, 197 5.7. OTHER
ANALGESICS, 197 5.8. GENERAL COMMENTS, 197 6. CONCLUSION, 200
REFERENCES, 201 11. ANTIINFECTIVE DRUGS, 204 1. THE DRUGS, 204 2.
SPECIFIC METHODS, 204 2.1. AGRANULOCYTOSIS, 204 2.2. APLASTIC ANEMIA,
207 3. RESULTS, 208 3.1. AGRANULOCYTOSIS, 208 3.2. APLASTIC ANEMIA, 210
4. SUMMARY OF RESULTS AND CONSIDERATION OF VALIDITY, 210 5. COMMENTS,
212 6. CONCLUSION, 214 REFERENCES, 215 12. ANTITHYROID DRUGS, 217 1. THE
DRUGS, 217 2. SPECIFIC METHODS, 217 2.1. AGRANULOCYTOSIS, 217 2.2.
APLASTIC ANEMIA, 218 3. RESULTS, 219 3.1. AGRANULOCYTOSIS, 219 3.2.
APLASTIC ANEMIA, 219 4. SUMMARY OF RESULTS AND CONSIDERATION OF
VALIDITY, 220 5. COMMENTS, 222 6. CONCLUSION, 223 REFERENCES, 224 13.
CARDIOVASCULAR DRUGS AND DIURETICS, 226 1. THE DRUGS, 226 2. SPECIFIC
METHODS, 226 CONTENTS XXI 2.1. AGRANULOCYTOSIS, 226 2.2. APLASTIC
ANEMIA, 230 3. RESULTS, 231 3.1. AGRANULOCYTOSIS, 231 3.2. APLASTIC
ANEMIA, 238 4. SUMMARY OF RESULTS AND CONSIDERATION OF VALIDITY, 238 5.
COMMENTS, 239 6. CONCLUSION, 242 REFERENCES, 242 14. PSYCHO TROPIC DRUGS
AND ANTIHISTAMINES, 244 1. THE DRUGS, 244 2. SPECIFIC METHODS, 244 2.1.
AGRANULOCYTOSIS, 244 2.2. APLASTIC ANEMIA, 247 3. RESULTS, 248 3.1.
AGRANULOCYTOSIS, 248 3.2. APLASTIC ANEMIA, 251 4. SUMMARY OF RESULTS AND
CONSIDERATION OF VALIDITY, 251 5. COMMENTS, 254 5.1. BENZODIAZEPINES,
254 5.2. ANTIDEPRESSANTS, 254 5.3. PHENOTHIAZINES, 255 5.4.
BARBITURATES, 256 5.5. OTHER PSYCHOTROPIC DRUGS, 256 5.6.
ANTIHISTAMINES, 256 6. CONCLUSION, 257 REFERENCES, 257 15. MISCELLANEOUS
DRUGS, 259 1. THE DRUGS, 259 2. SPECIFIC METHODS, 259 2.1.
AGRANULOCYTOSIS, 259 2.2. APLASTIC ANEMIA, 261 3. RESULTS, 262 3.1.
AGRANULOCYTOSIS, 262 3.2. APLASTIC ANEMIA, 264 4. SUMMARY OF RESULTS AND
CONSIDERATION OF VALIDITY, 266 5. COMMENTS, 269 5.1. CORTICOSTEROID
DRUGS, 269 5.2. SULFONYLUREA DERIVATIVES, 269 5.3. ALLOPURINOL, 270 5.4.
ANTICONVULSANTS, 270 XXII CONTENTS 5.5. SULFASALAZINE, 270 5.6.
PENICILLAMINE, 271 5.7. GOLD SALTS, 271 5.8. TROXERUTIN, 271 6.
CONCLUSION, 272 REFERENCES, 272 16. FACTORS OTHER THAN DRUGS, 274 1.
INTRODUCTION, 274 2. SPECIFIC METHODS, 275 2.1. AGRANULOCYTOSIS, 275
2.2. APLASTIC ANEMIA, 277 2.3. ESTIMATION OF RISK, 278 3. RESULTS, 278
3.1. AGRANULOCYTOSIS, 278 3.2. APLASTIC ANEMIA, 281 4. SUMMARY OF
RESULTS AND CONSIDERATION OF VALIDITY, 284 5. COMMENTS, 286 5.1. MEDICAL
HISTORY, 286 5.2. ENVIRONMENTAL FACTORS, 289 6. CONCLUSION, 289
REFERENCES, 290 17. GENERAL CONCLUSIONS, 293 1. RISK ESTIMATION FOR
DISEASES WITH MULTIPLE CAUSES, 293 2. ETIOLOGICALLY RELEVANT RISK
INTERVALS, 295 3. REGIONAL VARIATION OF DRUG EFFECTS, 296 4. THE PUBLIC
HEALTH IMPACT OF DRUG-INDUCED AGRANULOCYTOSIS AND APLASTIC ANEMIA, 296 ;
, 5. THE STRENGTHS AND LIMITATIONS OF THE PRESENT STUDY, 298 5.1. THE
SCIENTIFIC PERSPECTIVE, 298 5.2. THE PUBLIC POLICY PERSPECTIVE, 300 6.
CONCLUDING REMARKS, 302 REFERENCES, 304 APPENDIX: ESTIMATION OF TOTAL
DRUG-ATTRIBUTABLE ETIOLOGICAL FRACTIONS, 303 APPENDIX 1. OVERALL
DISTRIBUTIONS OF DRUG USE IN CASES AND CONTROLS, 305 APPENDIX 2. PRIMARY
DIAGNOSES IN HOSPITAL CONTROLS, 376 CONTENTS XXIII APPENDIX 3. DRUG USE
IN HOSPITAL-ACQUIRED CASES OF AGRANULOCYTOSIS, 382 APPENDIX 4. LISTING
OF LOCALITIES INCLUDED IN THE STUDY REGIONS, 394 INDEX OF DRUG NAMES,
395 SUBJECT INDEX, 401
|
| any_adam_object | 1 |
| author_GND | (DE-588)141518006 |
| building | Verbundindex |
| bvnumber | BV005460984 |
| callnumber-first | R - Medicine |
| callnumber-label | RA645 |
| callnumber-raw | RA645.A53 |
| callnumber-search | RA645.A53 |
| callnumber-sort | RA 3645 A53 |
| callnumber-subject | RA - Public Medicine |
| ctrlnum | (OCoLC)23869236 (DE-599)BVBBV005460984 |
| dewey-full | 616.1/52 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.1/52 |
| dewey-search | 616.1/52 |
| dewey-sort | 3616.1 252 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02395nam a2200577 cb4500</leader><controlfield tag="001">BV005460984</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20141215 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">920807s1991 |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0195059832</subfield><subfield code="9">0-19-505983-2</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)23869236</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV005460984</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RA645.A53</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.1/52</subfield><subfield code="2">20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The drug etiology of agranulocytosis and aplastic anemia</subfield><subfield code="c">David W. Kaufman ... With contrib. by Hermann Heimpel ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York u.a.</subfield><subfield code="b">Oxford Univ. Press</subfield><subfield code="c">1991</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIII, 404 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Monographs in epidemiology and biostatistics</subfield><subfield code="v">18</subfield></datafield><datafield tag="610" ind1="1" ind2="4"><subfield code="a">International Agranulocytosis and Aplastic Anemia Study</subfield></datafield><datafield tag="610" ind1="2" ind2="4"><subfield code="a">International Agranulocytosis and Aplastic Anemia Study</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Agranulocytose - Épidémiologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anémie aplastique - Épidémiologie</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Granulopenie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Pancytopenie</subfield><subfield code="2">gtt</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacoépidémiologie</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Agranulocytosis</subfield><subfield code="x">Epidemiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Agranulocytosis</subfield><subfield code="x">chemically induced</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Anemia, Aplastic</subfield><subfield code="x">chemically induced</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Aplastic anemia</subfield><subfield code="x">Epidemiology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drugs</subfield><subfield code="x">Side effects</subfield><subfield code="x">Epidemiology</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Aplastische Anämie</subfield><subfield code="0">(DE-588)4228474-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Agranulozytose</subfield><subfield code="0">(DE-588)4141632-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Agranulozytose</subfield><subfield code="0">(DE-588)4141632-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Aplastische Anämie</subfield><subfield code="0">(DE-588)4228474-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Arzneimittelnebenwirkung</subfield><subfield code="0">(DE-588)4003134-2</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kaufman, David</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Heimpel, Hermann</subfield><subfield code="d">1930-2014</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)141518006</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Monographs in epidemiology and biostatistics</subfield><subfield code="v">18</subfield><subfield code="w">(DE-604)BV000004952</subfield><subfield code="9">18</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003417782&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-003417782</subfield></datafield></record></collection> |
| id | DE-604.BV005460984 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T16:29:56Z |
| institution | BVB |
| isbn | 0195059832 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-003417782 |
| oclc_num | 23869236 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XXIII, 404 S. |
| publishDate | 1991 |
| publishDateSearch | 1991 |
| publishDateSort | 1991 |
| publisher | Oxford Univ. Press |
| record_format | marc |
| series | Monographs in epidemiology and biostatistics |
| series2 | Monographs in epidemiology and biostatistics |
| spelling | The drug etiology of agranulocytosis and aplastic anemia David W. Kaufman ... With contrib. by Hermann Heimpel ... New York u.a. Oxford Univ. Press 1991 XXIII, 404 S. txt rdacontent n rdamedia nc rdacarrier Monographs in epidemiology and biostatistics 18 International Agranulocytosis and Aplastic Anemia Study Agranulocytose - Épidémiologie Anémie aplastique - Épidémiologie Granulopenie gtt Pancytopenie gtt Pharmacoépidémiologie Agranulocytosis Epidemiology Agranulocytosis chemically induced Anemia, Aplastic chemically induced Aplastic anemia Epidemiology Drugs Side effects Epidemiology Aplastische Anämie (DE-588)4228474-0 gnd rswk-swf Agranulozytose (DE-588)4141632-6 gnd rswk-swf Arzneimittelnebenwirkung (DE-588)4003134-2 gnd rswk-swf Agranulozytose (DE-588)4141632-6 s Arzneimittelnebenwirkung (DE-588)4003134-2 s DE-604 Aplastische Anämie (DE-588)4228474-0 s Kaufman, David Sonstige oth Heimpel, Hermann 1930-2014 Sonstige (DE-588)141518006 oth Monographs in epidemiology and biostatistics 18 (DE-604)BV000004952 18 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003417782&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | The drug etiology of agranulocytosis and aplastic anemia Monographs in epidemiology and biostatistics International Agranulocytosis and Aplastic Anemia Study Agranulocytose - Épidémiologie Anémie aplastique - Épidémiologie Granulopenie gtt Pancytopenie gtt Pharmacoépidémiologie Agranulocytosis Epidemiology Agranulocytosis chemically induced Anemia, Aplastic chemically induced Aplastic anemia Epidemiology Drugs Side effects Epidemiology Aplastische Anämie (DE-588)4228474-0 gnd Agranulozytose (DE-588)4141632-6 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| subject_GND | (DE-588)4228474-0 (DE-588)4141632-6 (DE-588)4003134-2 |
| title | The drug etiology of agranulocytosis and aplastic anemia |
| title_auth | The drug etiology of agranulocytosis and aplastic anemia |
| title_exact_search | The drug etiology of agranulocytosis and aplastic anemia |
| title_full | The drug etiology of agranulocytosis and aplastic anemia David W. Kaufman ... With contrib. by Hermann Heimpel ... |
| title_fullStr | The drug etiology of agranulocytosis and aplastic anemia David W. Kaufman ... With contrib. by Hermann Heimpel ... |
| title_full_unstemmed | The drug etiology of agranulocytosis and aplastic anemia David W. Kaufman ... With contrib. by Hermann Heimpel ... |
| title_short | The drug etiology of agranulocytosis and aplastic anemia |
| title_sort | the drug etiology of agranulocytosis and aplastic anemia |
| topic | International Agranulocytosis and Aplastic Anemia Study Agranulocytose - Épidémiologie Anémie aplastique - Épidémiologie Granulopenie gtt Pancytopenie gtt Pharmacoépidémiologie Agranulocytosis Epidemiology Agranulocytosis chemically induced Anemia, Aplastic chemically induced Aplastic anemia Epidemiology Drugs Side effects Epidemiology Aplastische Anämie (DE-588)4228474-0 gnd Agranulozytose (DE-588)4141632-6 gnd Arzneimittelnebenwirkung (DE-588)4003134-2 gnd |
| topic_facet | International Agranulocytosis and Aplastic Anemia Study Agranulocytose - Épidémiologie Anémie aplastique - Épidémiologie Granulopenie Pancytopenie Pharmacoépidémiologie Agranulocytosis Epidemiology Agranulocytosis chemically induced Anemia, Aplastic chemically induced Aplastic anemia Epidemiology Drugs Side effects Epidemiology Aplastische Anämie Agranulozytose Arzneimittelnebenwirkung |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=003417782&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV000004952 |
| work_keys_str_mv | AT kaufmandavid thedrugetiologyofagranulocytosisandaplasticanemia AT heimpelhermann thedrugetiologyofagranulocytosisandaplasticanemia |